Skip to main content

This website is intended exclusively for healthcare professionals residing and/or working in the UAE.

Real-world Efficacy and Safety of Teriflunomide in Multiple Sclerosis: an Expert Consensus for GCC

Development of consensus recommendations

Factors contributing to teriflunomide recommendation

Level of disease activity

Pregnancy status

Cost-effectiveness of a drug

Established tolerability and safety profile

Monitoring burden

COVID-19 status

Patient preference

Established tolerability and safety profile

Expert consensus and recommendations for teriflunomide usage

COVID-19: Coronavirus disease 2019; GCC: Gulf Council Countries; MS: Multiple sclerosis; RRMS: Relapsing-remitting multiple sclerosis. this study has not been reviewed by SFDA

Alroughani R, Inshasi J, Al Khawajah M, et al. Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: An expert consensus narrative review. Mult Scler J Exp Transl Clin. 2022;8(1):1–10.

MAT-BH-2300590-V1-Oct.2023

YOU WILL NOW BE LEAVING THE SITE

By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.

Continue

This website is intended exclusively for healthcare professionals residing and/or working in the UAE.

Please choose if you are a healthcare professional and wish to continue on this site or if you are a member of the public to be redirected to the Sanofi website.